Quintiles Phase One Clinical Trials India Profile
Key Indicators
- Authorised Capital ₹ 38.00 Cr
as on 14-05-2024
- Paid Up Capital ₹ 36.57 Cr
as on 14-05-2024
- Company Age 15 Year, 5 Months
- Last Filing with ROC 31 Mar 2020
- Revenue -95.71%
(FY 2016)
- Profit -170.66%
(FY 2016)
- Ebitda -266.59%
(FY 2016)
- Net Worth -51.44%
(FY 2016)
- Total Assets -1.51%
(FY 2016)
About Quintiles Phase One Clinical Trials India
- CIN/LLPIN
U73100TG2009FTC064239
- Company No.
064239
- Company Classification
Private Limited Foreign Company Incorporated In India
- Incorporation Date
03 Jul 2009
- Date of AGM
29 Jun 2020
- Date of Balance Sheet
31 Mar 2020
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Company Details
- Location
Hyderabad, Telangana, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Quintiles Phase One Clinical Trials India?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Khusboo Singhvi | Company Secretary | 24-Apr-2019 | Current |
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Nilanjan Sinha  | Director | 14-Nov-2016 | Current |
| Arjun Aiyar | Director | 01-Nov-2016 | Current |
| Haripprasad Kovalamuri | Director | 15-May-2013 | Current |
Financial Performance and Corporate Structure Insights of Quintiles Phase One Clinical Trials India.
Quintiles Phase One Clinical Trials India Private Limited, for the financial year ended 2016, experienced significant reduction in revenue, with a 95.71% decrease. The company also saw a substantial fall in profitability, with a 170.66% decrease in profit. The company's net worth observed a substantial decline by a decrease of 51.44%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Quintiles Phase One Clinical Trials India?
In 2017, Quintiles Phase One Clinical Trials India had a promoter holding of 100.00%. The company had 1 Associate company. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Excel Life Sciences Private LimitedActive 19 years 27 daysNilanjan Sinha and Arjun Aiyar are mutual person
Sapien Biosciences Private LimitedActive 12 years 8 monthsHaripprasad Kovalamuri is a mutual person
Iqvia Rds (India) Private LimitedActive 22 years 29 daysNilanjan Sinha and Arjun Aiyar are mutual person
- Iqvia Analytics Services Private LimitedActive 21 years 18 days
Nilanjan Sinha and Arjun Aiyar are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Quintiles Phase One Clinical Trials India?
Unlock and access historical data on people associated with Quintiles Phase One Clinical Trials India, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Quintiles Phase One Clinical Trials India, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Quintiles Phase One Clinical Trials India's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
_PRIVATE_LIMITED_354462.webp){kind=small}
